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Microvascular Angina and the Continuing Dilemma
of Chest Pain With Normal Coronary Angiograms
Richard O. Cannon III, MD
Bethesda, Maryland
Since initial reports over 4 decades ago, cases of patients with angina-like chest pain whose coronary angio-
grams show no evidence of obstructive coronary artery disease and who have no structural heart disease con-
tinue to be a common occurrence for cardiologists. Many features of this patient population have remained con-
stant with successive reports over time: a female predominance, onset of symptoms commonly between 40 and
50 years of age, pain that is severe and disabling, and inconsistent responses to conventional anti-ischemic ther-
apy. Because patients may have had abnormal noninvasive testing that led to performance of coronary angiog-
raphy, investigators have sought to show an association of this syndrome with myocardial ischemia. Abnormali-
ties in coronary flow and metabolic responses to stress have been reported by several groups, findings
consistent with a microvascular etiology for ischemia and symptoms, but others have questioned the presence
of ischemia, even in patients selected for abnormal noninvasive testing. Despite considerable efforts by many
groups over 4 decades, the syndrome remains controversial with regard to pathophysiology, diagnosis, and
management. (J Am Coll Cardiol 2009;54:877–85) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.080i
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cs coronary angiography became more widely practiced
n the 1960s, it was soon apparent that not all patients
ith clinical suspicion of coronary artery disease (CAD)
ad obstruction of epicardial coronary arteries. Several
ublished series, including the National Heart, Lung,
nd Blood Institute-sponsored CASS (Coronary Artery
urgery Study) and the WISE (Women’s Ischemia Syn-
rome Evaluation) study, have reported that up to
ne-half of patients undergoing coronary angiography are
ound to have normal or nonobstructed epicardial coro-
ary arteries (1–3). In 1967, Likoff et al. (4) reported on
5 women ranging in age from 30 to 53 years with chest
ain despite normal coronary angiograms (CPNCA), but
ith electrocardiographic (ECG) abnormalities at rest
ST-segment depression or T-wave inversion) that were
ccentuated by exercise. Despite the ECG changes dur-
ng exercise, the hemodynamic response—as assessed by
ulmonary artery pressure, cardiac output, and oxygen
onsumption—was reported as normal in the 8 patients
n whom these measurements were made. The authors
f this article stated that “usual therapy of CAD was
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009, accepted March 17, 2009.neffective and unwarranted” in this setting (4). That
ame year, Kemp et al. (5) reported on a series of 50
atients (62% women) with CPNCA, commenting that
s a group, “these patients may frequently have the most
evere pain syndromes, often proving refractory to con-
entional forms of therapy.” Of the 41 patients who
nderwent metabolic study during isoproterenol stress,
1 showed myocardial lactate production supportive of
yocardial ischemia. Of these 11 patients, 4 had ischemic-
ppearing ECGs during exercise stress; however, 5 addi-
ional patients with ischemic-appearing ECGs during
xercise stress did not show myocardial lactate production
uring isoproterenol infusion. In a 1973 editorial, Kemp
6) noted that the heterogeneity of patients included in
tudies of patients with CPNCA makes it difficult to
erive clinical or mechanistic insights about this syn-
rome. The term “syndrome X” was used in this editorial
based on group X in the article under discussion) to
enote the uncertainty of chest pain etiology in these
atients, a term subsequently used by other investigators,
ut often with different criteria for its definition.
Twenty-six years ago, our group considered whether
mpaired coronary microcirculatory dilator responsiveness
ould limit blood flow response to stress, producing myo-
ardial ischemia and angina, and published our initial
ndings during the inaugural year of the Journal (7). Epstein
nd I subsequently proposed microvascular angina as a
uitable descriptor for this syndrome (8). Abnormalities in
oronary flow and metabolic responses to stress were re-
orted over the years by several groups, findings consistent
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Microvascular Angina September 1, 2009:877–85with a microvascular etiology (by
default, based on normal coro-
nary angiograms) for ischemia
and symptoms. Others, however,
have questioned an ischemic
cause for symptoms, even in pa-
tients selected for abnormal non-
invasive testing such as ischemic
appearance of stress ECG, des-
ignated by some groups as having
syndrome X. In 1992, Camici,
Epstein, and I wrote a review
article entitled Pathophysiological
Dilemma of Syndrome X (9). De-
spite considerable efforts by many
groups since that time, the syn-
drome remains controversial with
egard to pathophysiology, diagnosis, and management.
Despite differences of opinion regarding cardiac versus
oncardiac mechanisms of chest pain in this population,
ost groups have reported that patients with CPNCA and
tructurally normal hearts have a better prognosis with
egard to serious cardiac events (myocardial infarction,
ardiovascular death) compared with CAD patients (10–14).
lthough reassurance helps many patients, most continue to
ave chest pain resulting in emergency room evaluations,
ospitalizations, and repeat cardiac catheterizations, with
dverse effects on quality of life, employment, and health
are costs (15–18).
ocus on the Coronary Microcirculation
n response to surrounding myocardial metabolic condi-
ions, arterioles dilate or constrict to match flow appropriate
o myocardial oxygen demands. Micropuncture measure-
ents of pressure in small subepicardial arteries of the
eating cat heart, however, showed that 40% to 50% of the
otal coronary resistance is imposed by pre-arteriolar arteries
etween 100 and 300 m in diameter (19,20). The discov-
ry of endothelium-derived relaxing factors (21)—nitric
xide (NO) in particular (22)—led to numerous studies of
he role of the endothelium in coronary physiology, includ-
ng levels of the circulation distal to epicardial arteries. In
his regard, inhibition of NO synthesis with the L-arginine
ntagonist NG-monomethyl-L-arginine (L-NMMA) in-
reased basal coronary vascular resistance and blunted the
asodilator response to the endothelium-dependent agonist
cetylcholine in isolated perfused hearts (23). Small arteries
100- to 300-m diameter) and arterioles from cholesterol-
ed animals contracted in response to doses of acetylcholine
hat produced relaxation in similar-sized small arteries from
ontrol animals, despite equivalent relaxation to an NO
onor in the 2 groups (24–26). Microscopic examination of
he vascular segments from these studies showed the endo-
Abbreviations
and Acronyms
CAD  coronary artery
disease
CPNCA  chest pain
despite normal coronary
angiograms
ECG  electrocardiographic
L-NMMA  NG-monomethyl-
L-arginine
MRI  magnetic resonance
imaging
NMR  nuclear magnetic
resonance
NO  nitric oxidehelium to be structurally intact and free of atherosclerosis, although small lipid deposits or vacuoles were commonly
een within endothelial cells.
Bioavailability of NO may be diminished in experimental
ettings by a combination of reduced synthesis (which may
e selective for specific signal transduction pathways) and
ccelerated degradation, resulting in impaired endothelium-
ependent vascular relaxation and dilation. In this regard,
ccumulation of methylated arginines such as asymmetric
imethylarginine may compete with L-arginine for the
ubstrate binding site on NO synthase (27). Also, NO may
e degraded to biologically inactive nitrogen oxide com-
ounds by the action of superoxide anions, which may be
ncreased in hypercholesterolemia (28).
he Coronary Microcirculation in Humans
everal groups have reported evidence for dysfunction of the
oronary circulation at a level too small to be assessed
isually by measurement of coronary flow responses to
ndothelium-dependent and endothelium-independent va-
odilators in patients undergoing cardiac catheterization,
enerally for chest pain evaluation (29–31). Quyyumi et al.
31) investigated the contribution of NO to coronary
irculatory dynamics by infusing L-NMMA into the coro-
ary arteries of 31 patients (17 women) with CPNCA,
lthough most had 1 or more risk factors for atherosclerosis.
nhibition of NO synthesis caused a 10% to 15% constric-
ion of epicardial arteries and a 15% to 20% reduction in
oronary blood flow in patients who had no risk factors for
therosclerosis (Fig. 1). In contrast, patients with risk
actors had less of a constrictor effect on the coronary
irculation, consistent with reduced NO bioactivity. Fur-
her, co-infusion of L-NMMA with acetylcholine caused
reater attenuation of the dilator effects of this agonist in
atients without risk factors than in those with risk factors,
ndicating that the effect of acetylcholine on normal arteries,
egardless of size, is largely mediated through enhanced NO
elease (Fig. 2). Coronary microvascular dysfunction in
ome cases, however, may be independent of the endothe-
ium. Thus, Reis et al. (32) of the WISE study group
eported that of 159 women undergoing invasive study, 74
47%) had what they defined as subnormal coronary flow
esponses (2.5 ratio increase from baseline) to intracoro-
ary adenosine. Age and the number of years post-
enopause correlated inversely with reduced coronary flow
eserve, but not lipid and hormone levels, blood pressure, or
eft ventricular ejection fraction. A subsequent report from
he WISE study group with 210 women undergoing this
esting indicated that conventional atherosclerosis risk fac-
ors accounted for 20% of the observed variability in the
oronary flow response to adenosine, suggesting the role of
ther yet-unidentified factors responsible for microvascular
ysfunction (33).
The investigators of these studies concluded that micro-
ascular dysfunction may exist in patients with CPNCA,
nd may limit coronary flow during stress. The clinical
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September 1, 2009:877–85 Microvascular Anginamplications of these findings, however, are uncertain:
imilar abnormalities of coronary microvascular function
ay exist in asymptomatic subjects who have no indication
or cardiac catheterization and invasive study of coronary
ynamics.
he Case for Myocardial Ischemia
everal conditions have been proposed to account for
oronary microvascular dysfunction, including altered auto-
omic tone (34,35), insulin resistance (36–38), enhanced
on transport across cell membranes (39), increased
ndothelin-1 release (40,41), estrogen deficiency (42), and
ndothelial dysfunction (43–45). In many cases, patients
ere selected for invasive study based on an abnormal test
esult, such as from treadmill stress ECG or nuclear
erfusion imaging, consistent with inducible ischemia. Such
Figure 1 Contribution of NO to Epicardial
and Microvascular Coronary Tone
The effect of risk factors for coronary atherosclerosis on the change in resting
coronary vascular tone with NG-monomethyl-L-arginine (L-NMMA), an antagonist
of nitric oxide (NO) synthesis. The percent change in the coronary vascular
resistance, flow, and proximal and distal epicardial diameters with L-NMMA are
compared in patients with 1 risk factor (open circles) and in patients without
risk factors (solid circles). Results expressed as mean  SEM. †p  0.02
denotes differences in the response to L-NMMA by repeat-measures analysis
of variance between patients with and patients without risk factors. *p  0.05
and **p  0.01 denote differences between rest and post–L-NMMA measure-
ments in each group. Reprinted, with permission, from Quyyumi et al. (31).est results, however, could be not only false positive forpicardial CAD (by selection), but also false positive for
schemia, whatever the etiology. Accordingly, metabolic
vidence for ischemia might support claims of coronary
icrovascular dysfunction sufficient to limit appropriate
lood to myocardium during stress. Thus, Buffon et al. (46)
nvestigated metabolic evidence of ischemia during stress by
easuring lipid hydroperoxides and conjugated dienes—
olecules generated on reoxygenation of ischemic tissue—as
etabolic markers of ischemia in arterial and great cardiac vein
lood. Samples were drawn before and after rapid atrial pacing
n 9 patients (4 women) with CPNCA, 7 of whom had
schemic-appearing ST-segment depression during exercise
tress and 5 of whom had reversible nuclear perfusion defects.
Figure 2 Atherosclerosis Risk Factors and
Coronary Tone During Endothelial Stimulation
The impact of risk factors for coronary atherosclerosis on the vascular effects
of acetylcholine before and after inhibition of nitric oxide synthesis with
NG-monomethyl-L-arginine (L-NMMA). The percent change in the coronary vascu-
lar resistance, flow, and proximal and distal epicardial diameters with acetyl-
choline are compared in patients with 1 risk factor (open circles) and in
patients without risk factors (solid circles) for atherosclerosis. Responses to
the peak dose of acetylcholine are compared before and after L-NMMA in the 2
groups. Results expressed as mean  SEM. †p  0.03 denotes differences in
the response to acetylcholine between patients with and patients without risk
factors. *p  0.05 and **p  0.01 denote differences between control and
post–L-NMMA measurements in each group. Reprinted, with permission, from
Quyyumi et al. (31).
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Microvascular Angina September 1, 2009:877–85hese measurements were compared with those of 5 patients
ith mitral valve disease who underwent this study and served
s control subjects. Curiously, levels of these molecules were
igher in great cardiac vein blood than arterial blood before
acing in patients, whereas the reverse was true in control
ubjects. In patients, but not control subjects, great cardiac
enous levels of these molecules increased after pacing (160
eats/min or heart rate at development of ST-segment depres-
ion for 3 min) that induced ST-segment depression and chest
ain in all but 1 patient.
Buchthal et al. (47) from the WISE study group reported
hat 7 of 35 women with CPNCA who underwent nuclear
agnetic resonance (NMR) spectroscopy had findings com-
atible with myocardial ischemia during repetitive hand-
rip exercise. This conclusion was based on a reduction in
pectral signals from the phosphate of phosphocreatine
elative to the phosphates of adenosine triphosphate that
as similar to the decline in the ratio of these high-energy
hosphate spectra recorded in patients with CAD. The
requency of exercise-induced nuclear perfusion defects and
bnormal brachial artery endothelial testing, however, was
imilar for the 7 women with reduction in the ratio of
igh-energy phosphate spectra and the 28 women with
esser reduction (or actual increases) in these spectra. No
oronary flow dynamic data were reported to ascertain
elevance to invasive measures of microvascular function.
agnetic Resonance Imaging (MRI)
nd Subendocardial Ischemia
nvasive measures of coronary microvascular dynamics and
erformance of NMR spectroscopy are unavailable to most
ardiologists. Further, widely accepted values for normal
ersus abnormal responses to these tests are lacking. Cardiac
RI is being used with increasing frequency to show
schemia in patients with suspected CAD, including the
mergency department setting for patients presenting with
hest pain, with sufficient resolution to show subendocardial
schemia or infarction (48). Panting et al. (49) performed
ardiac MRI in 20 patients (16 women) with CPNCA and
schemic-appearing ECG responses to exercise stress and in
0 age- and sex-matched control subjects. Fourteen of the
atients had undergone nuclear perfusion imaging studies.
one showed reversible perfusion abnormalities after stress
o suggest inducible myocardial ischemia. Images were
btained at baseline and during adenosine infusion to dilate
he coronary microcirculation and maximally increase cor-
nary blood flow. In control subjects, adenosine similarly
ncreased perfusion in the endocardium and the epicardium
y analysis of short-axis slices of the left ventricle. In
ontrast, patients showed less increase in endocardial per-
usion but preserved increase in epicardial perfusion in
esponse to adenosine. During the adenosine infusion, 19 of
0 patients experienced chest pain that was often intense in
everity, whereas 4 of 10 control subjects experienced chest
ain that was generally mild in severity. The investigators toncluded that coronary microvascular dysfunction may limit
ppropriate increases in endocardial blood flow. Left unex-
lained is why ischemic chest pain should have occurred when
ndocardial perfusion was not actually reduced by adenosine
n this study.
On the other hand, Vermeltfoort et al. (50) performed
denosine-stress cardiac MRI in 20 patients (15 women)
ith CPNCA—all of whom had ischemic-appearing ECGs
nd/or reversible nuclear perfusion defects during exercise
tress—and reported comparable increases in subendocar-
ial and subepicardial signal intensity after adenosine infu-
ion. As highlighted by Camici (51) in an accompanying
ditorial, transient reductions in subendocardial signal in-
ensity, commonly noted in this study, are likely an artifact
f the first-pass sequence, unlike the sustained signal loss in
he subendocardium seen in patients with CAD, which is
enerally believed to represent subendocardial ischemia.
he Case Against Myocardial Ischemia
lthough many of the studies cited previously support the
aradigm that coronary microvascular dysfunction in the
bsence of structural heart disease may precipitate myocar-
ial ischemia, other studies—beginning with the report
rom the Montreal Heart Institute (52) that prompted the
973 Kemp editorial (6)—have questioned the existence of
yocardial ischemia in patients with CPNCA who have
tructurally normal hearts, including those with ischemic-
ppearing stress ECGs or other noninvasive testing sugges-
ive of inducible ischemia. Such studies have included
nalysis of coronary sinus metabolites of carbohydrates and
atty acids (53) and pH monitoring of coronary sinus blood
efore and during rapid atrial pacing (54), concluding that
ost patients with CPNCA do not show metabolic evi-
ence of myocardial ischemia despite chest pain with stress.
Other groups have evaluated cardiac function during
tress to determine whether ischemic appearance of the
CG during stress is associated with diminished regional or
lobal wall motion consistent with inducible myocardial
schemia, as recognized in CAD. Thus, Nihoyannopoulos
t al. (55) reported normal left ventricular systolic function
y echocardiography immediately after exercise and during
apid atrial pacing in 18 patients with CPNCA despite
xperiencing chest pain with ischemic-appearing ST-
egment depression during these stresses. We evaluated 70
onsecutive patients (44 women) with CPNCA, of whom
2 had ischemic-appearing ECG responses during treadmill
xercise and 13 had reversible perfusion defects, albeit
ithout correlation between these 2 noninvasive tests (56).
he results of exercise testing and dobutamine stress echo-
ardiography from these 70 patients were compared with
hose of 26 healthy subjects. The transesophageal route for
maging was used to maximize the number of ventricular
egments visualized and the quality of images for assessment
f contractility. Dobutamine infused in stepwise increments
o 40 g/kg/min induced chest pain in 59 patients but in
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September 1, 2009:877–85 Microvascular Anginaone of the control subjects. Ischemic-appearing ST-
egment depression developed in 22 patients and in 2
ontrol subjects. Wall motion abnormalities occurred in
one of the patients or control subjects, and no differences
ere observed in transmural contractile response to dobut-
mine between patients and control subjects (Fig. 3).
ndeed, of the 70 patients, the quantitative myocardial
ontractile response to dobutamine was virtually identical in
he 22 patients with ST-segment depression and the 48
atients without this ECG response during infusion.
Thus, despite the frequent provocation of characteristic
hest pain, including those with ischemic-appearing ST-
egment depression, patients with CPNCA do not show
oncomitant regional wall motion abnormalities, but instead
how a quantitatively normal myocardial contractile re-
ponse to stress that argues against inducible ischemia. In
ebuttal to this conclusion, however, Maseri et al. (57)
roposed that patchy microvascular constriction (or absence
f appropriate vasodilation) may produce myocardial isch-
mia during stress that does not affect myocardial contrac-
ility because of compensatory vasodilation of adjacent
rterioles.
rognostic Implications of
oronary Endothelial Dysfunction
lthough reports from large cohorts of patients with
PNCA suggest a benign prognosis (10–18), at least for
ife-threatening cardiac events, studies incorporating assess-
ent of endothelial function indicate that subsets of pa-
ients may be at higher risk of serious cardiovascular events
58–61). These studies support the prognostic significance
Figure 3 Left Ventricular Functional Responses to Stress
Comparison of the quantitative myocardial response to the infusion of incre-
mental doses of dobutamine in healthy control subjects (open circles) and in
patients with chest pain and normal coronary angiograms (solid circles).
Results expressed as mean  SEM. The p value corresponds to comparison of
the different responses by repeat-measures analysis of variance. Reprinted,
with permission, from Panza et al. (56). NS  not significant.f coronary endothelial dysfunction at the epicardial oricrovascular level. The relevance to patients with
PNCA, however, is unclear. Similar demonstration of
ndothelial dysfunction in a population of comparable age
nd risk factor profile, but free of chest pain symptoms,
ight have identified similar cardiovascular risk.
Investigators from the WISE study group reported the
rognostic implications of NMR spectroscopy testing in
omen with CPNCA, extending findings from their pre-
ious publication (62). This series included 74 women with
o obstructive plaques on coronary angiograms, of whom 60
ad no reduction in the ratio of phosphocreatine-to-
denosine triphosphate signals during hand-grip stress and
4 showed reduction in this ratio. At 3 years, 87% of the
roup with a normal ratio of high-energy phosphate signals
ere free of cardiovascular events, versus 57% in the
bnormal spectral signal ratio group. The difference in
vents, however, was primarily attributable to the increased
requency of repeat hospitalizations for chest pain and
epeat coronary angiography, and not to myocardial infarc-
ion or cardiovascular death.
bnormal Cardiac Pain Perception:
he Sensitive Heart
he observation that patients with CPNCA commonly
xperience their characteristic chest pain during the perfor-
ance of diagnostic cardiac catheterization has led several
roups to consider abnormal cardiac pain perception as a
undamental abnormality in this patient population, initially
hown by simple catheter movement or saline injections
ithin the heart (63–67). We found that in 36 patients (21
omen) with CPNCA, characteristic chest pain could be
rovoked in 86% by electrical stimulation (right ventricular
Figure 4 Chest Pain During Cardiac
Catheterization: The Sensitive Heart
Prevalence of typical chest pain experienced during cardiac catheterization in
36 patients with chest pain and normal coronary angiograms (CPNCA), 44
patients with coronary artery disease (CAD), and 10 patients with valvular heart
disease (VHD) provoked by pacing from apex of right ventricle at 5 beats over
resting heart rate and/or injection of contrast media into the left coronary
artery. Adapted and reprinted with permission from Cannon et al. (64).
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Microvascular Angina September 1, 2009:877–85acing) at a heart rate 5 beats faster than their resting heart
ate, with the pain worsened by increasing the stimulus
ntensity (64). In over one-half of these patients, pain could
lso be provoked by simply injecting contrast media into the
eft coronary artery (Fig. 4). In contrast, pain responses to
hese maneuvers were rarely encountered in patients with
AD or valvular heart disease. Other potent stimuli for pain
rovocation in CPNCA patients are dipyridamole and
denosine infusion (64,65). Exaggerated pain sensitivity has
lso been shown within the esophagus of patients with
PNCA (68), lending speculation that the mechanism of
xaggerated visceral pain sensitivity may be neurophysi-
logically linked to whatever is responsible for anxiety and
anic disorders commonly noted in patients with CPNCA
67,69–71).
Rosen et al. (72) measured regional cerebral blood flow by
ositron emission tomography as an index of neuronal
ctivity at rest and during dobutamine stress in 8 patients (6
omen) with CPNCA and ischemic-appearing ECG re-
ponses to exercise stress and in 8 control subjects. Dobut-
mine precipitated severe chest pain and ST-segment de-
ression in all patients, although echocardiography showed
ncreased left ventricular contractility. Patients and control
ubjects showed similar increases in blood flow in the
ypothalamus, thalami, right orbitofrontal cortex, and an-
erior temporal lobes. In patients, but not in control sub-
ects, increased blood flow was also noted in the right
nterior insula/frontal operculum junction. In a previous
tudy of identical design but with CAD patients, dobut-
mine infusion provoked chest pain and echocardiographic
vidence of myocardial ischemia. No increased blood flow in
he right insula was noted in these patients (73). Thus,
atients with this syndrome may have an altered pattern of
ortical activation by visceral afferent signals, which could
Figure 5 Microvascular Angina: Connecting the Dots
Future research should establish a coherent pathophysiology that links coronary m
relevant, testing that separates those patients whose symptoms are caused by m
ple groups, and strategies for effective management must be supported by randomontribute to abnormal pain perception during cardiac stress
ven in the absence of ischemia.
reatment Trials and Management Approaches
erhaps the most frustrating aspect of the syndrome of
PNCA is the management of chest pain symptoms, as was
ecognized in the earliest reports in the literature. Numerous
herapies have been reported to be successful in clinical trials
enerally including small numbers of patients, including
itrates (74), beta-blockers (75,76), calcium-channel block-
rs (77), angiotensin-converting enzyme inhibitors (78),
ricyclic antidepressant (79), aminophylline (80), estrogen
eplacement therapy (81) and L-arginine (82). The WISE
tudy group is currently conducting randomized clinical
rials with quinapril (NCT00150826) and ranolazine
NCT00570089). The clinical experience, however, has
enerally been that pain relief with medical therapy is not
ustained over time, and patients are commonly prescribed a
arge number of drugs. Another management consideration
s gastroesophageal testing, which may reveal acid reflux
isease or esophageal motility disorders (68). Other groups
ave proposed nonpharmacologic approaches to pain symp-
oms in this patient population, including exercise training
83), transcendental meditation (84), cognitive behavioral
herapy (85), and transcutaneous electrical nerve stimulation
r spinal cord stimulation (86–88).
Absence of a widely accepted understanding of patho-
hysiology and approach to diagnosis and treatment should
ot preclude a sympathetic appreciation of symptoms,
hich can be debilitating for some patients. My manage-
ent approach is to perform vasodilator stress cardiac MRI:
f convincing evidence of subendocardial ischemia is
resent, then anti-ischemic therapy seems appropriate. If no
schemia is evident, I use a combination of beta-blocker and
scular dysfunction with myocardial ischemia. For the diagnosis to be clinically
ial ischemia from those whose pain is nonischemic should be validated by multi-
linical trials. CV  cardiovascular.icrova
yocard
ized c
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September 1, 2009:877–85 Microvascular Anginamipramine, and encourage enrollment in an aerobic exer-
ise program. This approach is supported by several of the
andomized clinical trials mentioned previously (75,76,79,83),
ut the combination has not been validated by a proper clinical
rial design.
uture Research Directions
he studies cited in this review have generally focused on
elected aspects of the syndrome of CPNCA in the absence
f structural heart disease. Necessary to resolve the continu-
ng debate and legitimize a specific diagnosis (e.g., micro-
ascular angina) is to “connect the dots” by defining a
oherent pathophysiology that links coronary microvascular
ysfunction by some mechanism—and localized to that level
f the circulation by exclusion of epicardial disease, perhaps
sing computerized tomographic coronary angiography—with
vidence of myocardial ischemia (Fig. 5). For the diagnosis
o be clinically relevant, testing that separates those patients
hose symptoms are caused by myocardial ischemia from
hose whose pain is nonischemic should be validated by
ultiple groups, and strategies for effective management
ust be supported by randomized clinical trials. This last
oint is critical because patients suffer from pain that is
usceptible to a placebo effect, without lasting benefit. If
onventional noninvasive stress testing cannot reliably iden-
ify patients with inducible ischemia as a cause of chest pain,
hen testing that is not widely available (such as NMR
pectroscopy) must be validated by several centers to support
eferral of patients for specialized testing. Greater experi-
nce with cardiac MRI, which is more widely available, may
upport use of this testing, but validation of findings from
ultiple centers is necessary. To be clinically useful, results
f such testing must translate into effective treatment and
mproved quality of life for patients.
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